ALX ONCOLOGY HOLDINGS INC Earnings Per Share Disclosure
(12) NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):
|
|
Year Ended |
|
|||||||||
|
|
December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Numerator: |
|
|
|
|
|
|
|
|
|
|||
Net loss |
|
$ |
(101,695 |
) |
|
$ |
(134,850 |
) |
|
$ |
(160,805 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|||
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
53,658,399 |
|
|
|
52,174,904 |
|
|
|
42,987,767 |
|
Net loss per share, basic and diluted |
|
$ |
(1.90 |
) |
|
$ |
(2.58 |
) |
|
$ |
(3.74 |
) |
Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented as the inclusion of all potential common stock outstanding would have been anti-dilutive.
The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2025, 2024 and 2023, because including them would have been anti-dilutive:
|
|
Year Ended |
|
|||||||||
|
|
December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Stock options issued and outstanding |
|
|
12,878,187 |
|
|
|
10,528,751 |
|
|
|
8,984,671 |
|
RSUs issued and outstanding |
|
|
240,433 |
|
|
|
898,755 |
|
|
|
949,669 |
|
PSUs issued and outstanding |
|
|
57,750 |
|
|
|
357,500 |
|
|
|
— |
|
Total |
|
|
13,176,370 |
|
|
|
11,785,006 |
|
|
|
9,934,340 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
| 2023 | Mar 7, 2024 | |
| 2022 | Mar 9, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.